Your Article Summary
See Latest ArticlesNew curcumin analogues exhibit enhanced growth-suppressive activity and inhibit AKT and signal transducer and activator of transcription 3 phosphorylation in breast and prostate cancer cells
Cancer Science, 07/01/09
Lin L et al. - The results indicate that FLLL11 and FLLL12 exhibit more potent activities than curcumin on the inhibition of STAT3, AKT, and HER-2/neu, as well as inhibit cancer cell growth and migration, and may thus have translational potential as chemopreventive or therapeutic agents for breast and prostate cancers.
Related Articles
Rethinking Screening for Breast Cancer and Prostate Cancer
JAMA, 10/23/09
Relevance Score: 83%
Low cholesterol may be sign of undiagnosed cancer
Reuters, 11/04/09
Relevance Score: 82%
New Drug Aims To Seek And Destroy Many Types Of Cancer
ScienceDaily, 10/07/09
Relevance Score: 82%
New drug aims to seek and destroy many types of cancer
EurekAlert, 10/06/09
Relevance Score: 82%
Breakthrough In Lab-on-chip For Fast Cancer Detection And Therapy
ScienceDaily, 10/29/09
Relevance Score: 81%
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Target genes suitable for silencing approaches and protein product interference in ovarian epithelial cancer
Cancer Treatment Reviews, 12/04/09
Dysregulation of Platelet-Derived Growth Factor beta-Receptor Expression by deltaNp73 in Neuroblastoma
Molecular Cancer Research, 12/04/09
Tissue transglutaminase 2 as a biomarker of cervical intraepithelial neoplasia (CIN) and its relationship to p16INK4A and nuclear factor kappaB expression
Virchows Archiv, 12/04/09
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
Bevacizumab and breast cancer: current therapeutic progress and future perspectives
Expert Review of Anticancer Therapy, 12/04/09
Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis
Cancer Treatment Reviews, 12/04/09
Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer
Cancer Treatment Reviews, 12/04/09
Today in Renal/Urologic...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/04/09